Positive outcome of FDA Advisory Committee meeting on patisiran for the treatment of the cardiomyopathy of ATTR amyloidosis
Alnylam Pharmaceuticals, Inc. announced the positive outcome of the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to discuss the supplemental New Drug Application (sNDA) for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis
The CRDAC voted 9:3 that the benefits of patisiran outweigh its risks for the treatment of the cardiomyopathy of ATTR amyloidosis.
ATTR amyloidosis is an underdiagnosed, rapidly progressive, debilitating and fatal disease caused by misfolded transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the heart, resulting in cardiomyopathy and heart failure. The cardiac manifestations associated with ATTR amyloidosis can have a devastating impact on patients’ lives and treatment options today are limited, with many patients continuing to progress on, or unable to access, current standard-of-care.
The positive decision by the FDA’s CRDAC panel of independent experts was based on a discussion of the data supporting the sNDA for patisiran, which include positive results from the APOLLO-B Phase III study that demonstrate favorable effects on functional capacity and health status and quality of life in patients with ATTR amyloidosis with cardiomyopathy relative to placebo, as measured by the 6-Minute Walk Test (6-MWT) and the Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) score, respectively.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins